Home | Find A Doctor | Contact Us

 

Phase 1/2 Study of PX-866 and Docetaxel in Patients with Solid Tumors


Principal Investigator: Benjamin Levy, MD
Time frame of study: Ongoing
Location of Study:

Mount Sinai Beth Israel
St.Luke's-Mount Sinai Roosevelt

Contact:

Continuum Cancer Research Program
(212) 844-6286

 

Summary:
The purpose of this study is to evaluate how effective docetaxel plus PX‑866 treatment is when given to patients with solid tumors due to advanced cancer of the lung, neck and head.  Docetaxel prevents cancer cells from growing by blocking certain structures in the cancer cell (microtubules), and is already commonly used for the treatment of various cancers.  PX-866 is a new experimental drug that is thought to prevent the growth of cancer cells by affecting a protein called PI-3K.  This study aims to purpose find out whether PX-866 in combination with docetaxel is better than docetaxel alone.


Eligibility and Treatment Plan:

  • Male or female of at 18 years of age
  • Locally advanced, recurrent, or metastatic non-small cell lung cancer, or squamous cell cancer of the head and neck
  • Disease or tumor that can be measured for changes to monitor growth
  • Adequate organ function (kidney, liver and heart)
  • Ability  to take physical care of yourself
  • Pregnant or nursing women are not eligible for this study.

Please call for more information.

 

 

Privacy Policy | Site Map
Copyright ©  Icahn School of Medicine at Mount Sinai | Mount Sinai Health System